candesartan has been researched along with Anemia in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
O'Meara, E | 1 |
Clayton, T | 1 |
McEntegart, MB | 1 |
McMurray, JJ | 1 |
Lang, CC | 1 |
Roger, SD | 1 |
Young, JB | 1 |
Solomon, SD | 1 |
Granger, CB | 1 |
Ostergren, J | 1 |
Olofsson, B | 1 |
Michelson, EL | 1 |
Pocock, S | 1 |
Yusuf, S | 1 |
Swedberg, K | 1 |
Pfeffer, MA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Anemia in Chronic Heart Failure: Etiology, Comparisons With Renal Disease, and Relationships With Biomarkers and Left Ventricular Remodeling.[NCT00834691] | 180 participants (Anticipated) | Observational | 2008-01-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 other study available for candesartan and Anemia
Article | Year |
---|---|
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Topics: Aged; Anemia; Benzimidazoles; Biphenyl Compounds; Female; Glomerular Filtration Rate; Heart Failure; | 2006 |